ArticleBiomedical optics express2022
Noninvasive measurement of the vital signs of cancer patients with a dual-path microbend fiber sensor.
Article in Biomedical optics express, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 23 citations in OpenAlex.
- Introduction to the feature issue: Advances in Optical Biosensors for Biomedical Applications.Biomedical optics express · 2024Article
- A Wearable Sandwich Heterostructure Multimode Fiber Optic Microbend Sensor for Vital Signal Monitoring.Sensors (Basel, Switzerland) · 2024Article
- Sleep condition detection and assessment with optical fiber interferometer based on machine learning.iScience · 2023Article
- Studying the effect of polymethyl methacrylate polymer opticals fibers (POFs) on the performance of composite materials based on the polyether ether ketone (PEEK) polymer matrix.Emergent materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel dual-path microbend fiber optic sensor is designed for noninvasive measurement of respiratory rate (RR) and heart rate (HR) for cancer patients. The performance of the microbend fiber sensor is assessed in two groups of cancer patients, cancer patients with pain and without pain, ranging from eighteen to ninety-six years old in a daily observational measurement with the sensor mattress under the mattress of the clinical bed. All the patients received standard clinical monitoring for evaluating the accuracy of our measurement results. The results of our study showed good consistency in the experimental results of RR and HR between the dual-path fiber sensor we proposed and the hospital equipment with average errors of 3.60 beats per minute (bpm) and 1.02 respiration per minute (rpm) in HR and RR measurement in cancer patients with pain and 1.87bpm and 1.27rpm in HR and RR measurement in cancer patients without pain, respectively. In HR monitoring, the single path microbend fiber optic sensor has 8035 minutes of data with a false report rate of 19.09%, while the dual-path microbend fiber optic sensor has 6188 minutes of data with a false report rate of 12.87%. The dual-path sensor has a smaller false report rate compared with the single path sensor due to pre-judgments of data with path 1 and path 2. To our best knowledge, it is the first time to propose and demonstrate a dual-path sensor to reduce the false report rate for HR and RR measurements. The results of the Blend-Altman method showed great agreement between our sensor and hospital standard monitor in HR and RR measurements. The independent sample t-test indicates that the HR of cancer patients may be an effective way to judge whether or not they have cancer pain. Our noninvasive dual-path microbend fiber sensor also showed the advantages of an easy fabrication process, simple structure, and low false report rate.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.